Ass. Prof. Balar shares the results of his study involving pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as bladder-sparing treatment for MIBC.
Ass. Prof. Balar shares the results of his study involving pembrolizumab in combination with gemcitabine and concurrent hypofractionated radiation therapy as bladder-sparing treatment for MIBC.